JUST IN: Trump Media has accumulated $2 BILLION in Bitcoin and Bitcoin-related securitiesTrump Media plans to continue acquiring Bitcoin and to convert its options into spot Bitcoin 🔥 https://t.co/NCXDZrlXd7 ...

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157181&from=4CLASS PERIOD: April 29, ...

BREAKING: 🇺🇸 TRUMP MEDIA BUYS $2 BILLION WORTH OF #BITCOIN AND BITCOIN-RELATED SECURITIES. https://t.co/xmFBjqsx0a ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Vestis Corporation during the specified class period of the upcoming lead plaintiff deadline on August 8, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Vestis Corporation, and investors who wish to serve as lead plaintiff must act by August 8, 2025 [2]. - The lawsuit alleges that Vestis provided misleading statements about its business growth potential while concealing material adverse facts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Petco Health and Wellness Company, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by August 29, 2025 [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Petco between January 14, 2021, and June 5, 2025, to discuss their legal options [1][3]. - A federal securities class action has been filed against Petco, with a reminder of the August 29, 2025, deadline for seeking lead plaintiff status [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Petco - The complaint alleges that Petco and its executives made false and misleading statements regarding the sustainability of its pandemic-related growth and business model [5]. - Specific allegations include overstating the strength of Petco's product strategy and downplaying the severity of operational issues [5]. - The complaint claims that these misrepresentations led to an overestimation of Petco's ability to achieve sustainable, profitable growth [5]. Group 3: Financial Performance - On June 5, 2025, Petco reported first-quarter financial results, revealing net sales of $1.5 billion, which is a 2.3% decline year-over-year [6]. - Following the financial report, Petco's stock price dropped by $0.85 per share, or 23.34%, closing at $2.78 per share on June 6, 2025 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of their Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the release of the financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [5][6]. Group 2: Impact on Stock Price - Following Novo Nordisk's announcement of ending its partnership with Hims due to legal violations, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [3][5]. Company Overview - Sarepta Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases, particularly those related to genetic disorders [3]. Legal Proceedings - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, which posed significant risks to patients [5]. Product Safety Issues - On March 18, 2025, Sarepta reported a patient death following treatment with ELEVIDYS, leading to a stock price drop of $27.81 per share, or 27.44%, closing at $73.54 [6]. - Following regulatory scrutiny, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies on April 4, 2025, resulting in a further stock price decline of $4.18 per share, or 7.13%, to close at $54.43 [7][8]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, prompting Sarepta to suspend shipments of ELEVIDYS for non-ambulatory patients and pause dosing in one clinical study, causing a significant stock price drop of $15.24 per share, or 42.12%, to close at $20.91 [9][10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the risk of acute liver failure associated with ELEVIDYS, leading to an additional stock price decline of $1.52 per share, or 8.01%, to close at $17.46 [10][11]. Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Sarepta to contact them for discussions about their legal rights and options [1][13].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to significant stock price declines [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Centene to contact them for legal options, particularly those who purchased securities between December 12, 2024, and June 30, 2025 [1][3]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Company Performance and Stock Impact - Centene provided positive statements to investors while concealing adverse facts about its enrollment and morbidity rates, leading to a significant loss of investor trust [5]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% in just one day [6].

Group 1 - The Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the August 12, 2025, lead plaintiff deadline for a class action lawsuit [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [2][5] Group 2 - The lawsuit alleges that during the class period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4] - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became public [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [3]